Park Eun-Kee, Thomas Paul S, Johnson Anthony R, Yates Deborah H
Research and Education Unit, Workers' Compensation (Dust Diseases) Board, School of Medical Sciences, Faculty of Medicine, University of New South Wales, and Department of Thoracic Medicine, St Vincent's Hospital, Darlinghurst, Sydney, Australia.
Clin Cancer Res. 2009 Feb 15;15(4):1362-6. doi: 10.1158/1078-0432.CCR-08-0360. Epub 2009 Jan 27.
Serum osteopontin levels in patients with malignant mesothelioma have been reported to be higher than in healthy subjects. This study assessed serum osteopontin levels in an asbestos-exposed population to test whether nonmalignant asbestos-related disorders could influence osteopontin levels.
This cross-sectional study evaluated serum osteopontin levels in 525 male subjects. Subjects were classified into six different diagnostic groups, including asbestosis (n=23), silicosis (n=20), diffuse pleural thickening (n=110), asbestosis and diffuse pleural thickening (n=13), pleural plaques (n=142), and healthy subjects with a history of asbestos exposure (n=217).
Mean serum osteopontin levels differed among the six groups (P<0.0001). Mean osteopontin values of the healthy individuals exposed to asbestos were significantly different from that of subjects with asbestosis (P<0.001) and diffuse pleural thickening (P<0.001). There was a significant difference in mean serum levels of osteopontin in healthy individuals exposed to asbestos (n=217) compared with the group mean of all subjects with asbestos-related disorders (n=288; P<0.0001).
Our results suggest that osteopontin levels are elevated in subjects with asbestos-related disorders without malignant mesothelioma. These data indicate that osteopontin, although reported to be useful for detecting malignant mesothelioma in asbestos-exposed individuals, may be influenced by nonmalignant processes.
据报道，恶性间皮瘤患者的血清骨桥蛋白水平高于健康受试者。本研究评估了石棉暴露人群的血清骨桥蛋白水平，以测试非恶性石棉相关疾病是否会影响骨桥蛋白水平。
这项横断面研究评估了525名男性受试者的血清骨桥蛋白水平。受试者被分为六个不同的诊断组，包括石棉肺（n = 23）、矽肺（n = 20）、弥漫性胸膜增厚（n = 110）、石棉肺和弥漫性胸膜增厚（n = 13）、胸膜斑（n = 142）以及有石棉暴露史的健康受试者（n = 217）。
六组之间的平均血清骨桥蛋白水平存在差异（P<0.0001）。接触石棉的健康个体的平均骨桥蛋白值与石棉肺患者（P<0.001）和弥漫性胸膜增厚患者（P<0.001）的平均骨桥蛋白值有显著差异。与所有患有石棉相关疾病的受试者的组均值（n = 288；P<0.0001）相比，接触石棉的健康个体（n = 217）的血清骨桥蛋白平均水平存在显著差异。
我们的结果表明，在没有恶性间皮瘤的石棉相关疾病患者中，骨桥蛋白水平升高。这些数据表明，骨桥蛋白虽然据报道可用于检测石棉暴露个体中的恶性间皮瘤，但可能会受到非恶性过程的影响。
